Human Recombinant CCL22 protein, His Tag (V2LY-0526-LY5505)

Name: Human Recombinant CCL22 protein, His Tag
SKU: V2LY-0526-LY5505
Rating: 5 (1 reviews)

See all CCL22 antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Expressed Host

E. coli

Protein Species

Human

Tag

His Tag

Protein Construction

This product is Human Recombinant CCL22 protein, His Tag consist of Amino Acid: 25-93 and predicts a molecular mass of 9.7 kDa.

Molecule Mass

9.7 kDa

Sequence

Amino Acid: 25-93

Species

Human

Formulations & Storage [For reference only, actual COA shall prevail!]

Purity

>90% as determined by SDS-PAGE

Endotoxin

Please contact us for more information.

Format

Lyophilized

Reconstitution

Allow the vial and reconstitution buffer to equilibrate to room temperature. Briefly centrifuge or tap down the vial to ensure that all lyophilized powder is collected at the bottom of the vial. For the reconstitution of this product, we recommend adding PBS or sterile water to achieve a final antibody concentration of 1 mg/mL. Allow the vial to reconstitute for 10-15 minutes at room temperature with gentle agitation. Avoid vigorous shaking that can cause foaming and antibody denaturation. Aliquot into volumes based on your experiment and store liquid protein at -20°C or -80°C for long time.

Buffer

Lyophilized from sterile PBS

Preservative

None

Storage

Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

More Infomation

Target

Full Name

C-C Motif Chemokine Ligand 22

Function

May play a role in the trafficking of activated/effector T-lymphocytes to inflammatory sites and other aspects of activated T-lymphocyte physiology. Chemotactic for monocytes, dendritic cells and natural killer cells. Mild chemoattractant for primary activated T-lymphocytes and a potent chemoattractant for chronically activated T-lymphocytes but has no chemoattractant activity for neutrophils, eosinophils, and resting T-lymphocytes. Binds to CCR4. Processed forms MDC(3-69), MDC(5-69) and MDC(7-69) seem not be active.

Biological Process

Antimicrobial humoral immune response mediated by antimicrobial peptide Source: UniProtKB
Cell-cell signaling Source: ProtInc
Cellular response to interferon-gamma Source: GO_Central
Cellular response to interleukin-1 Source: GO_Central
Cellular response to tumor necrosis factor Source: GO_Central
Chemokine-mediated signaling pathway Source: GO_Central
Chemotaxis Source: ProtInc
Cytokine-mediated signaling pathway Source: Reactome
G protein-coupled receptor signaling pathway Source: GO_Central
Immune response Source: ProtInc
Inflammatory response Source: GO_Central
Killing of cells of other organism Source: UniProtKB
Lymphocyte chemotaxis Source: GO_Central
Monocyte chemotaxis Source: GO_Central
Neutrophil chemotaxis Source: GO_Central
Positive regulation of ERK1 and ERK2 cascade Source: GO_Central
Positive regulation of GTPase activity Source: GO_Central
Response to virus Source: ProtInc
Signal transduction Source: ProtInc

Cellular Location

Secreted

PTM

The N-terminal processed forms MDC(3-69), MDC(5-69) and MDC(7-69) are produced by proteolytic cleavage after secretion from monocyte derived dendrocytes.

Xu, H., Lin, S., & Huang, H. (2021). Involvement of increased expression of chemokine C–C motif chemokine 22 (CCL22)/CC chemokine receptor 4 (CCR4) in the inflammatory injury and cartilage degradation of chondrocytes. Cytotechnology, 73(5), 715-726.

Dong, Y., Gao, S., Zhang, X., Kou, J., Liu, J., Ye, T., & Shen, H. (2021). CCL17 and CCL22 induce CCR4 receptor expression and promote cytokine-induced killer cells migration. Anti-cancer Drugs.

Kimura, S., Noguchi, H., Nanbu, U., & Nakayama, T. (2021). Macrophage CCL22 expression promotes lymphangiogenesis in patients with tongue squamous cell carcinoma via IL-4/STAT6 in the tumor microenvironment. Oncology Letters, 21(5), 1-11.

Baer, C., Kimura, S., Iacobucci, I., Feith, D. J., Walter, W., Meggendorfer, M., ... & Haferlach, T. (2020). Recurrent Mutations of the CC Motif Chemokine Ligand 22 (CCL22) Define a Distinct Subgroup of Chronic Lymphoproliferative Disorder of NK Cells (CLPD-NK). Blood, 136, 19.

Ohuchi, K., Fujimura, T., Lyu, C., Amagai, R., Muto, Y., & Aiba, S. (2020). Serum CCL22 levels decreased in parallel with disease activity in CCR4‐positive mycosis fungoides treated with mogamulizumab. Dermatologic Therapy, 33(6), e14099.

Huang, Y. H., Chang, C. Y., Kuo, Y. Z., Fang, W. Y., Kao, H. Y., Tsai, S. T., & Wu, L. W. (2019). Cancer‐associated fibroblast‐derived interleukin‐1β activates protumor C‐C motif chemokine ligand 22 signaling in head and neck cancer. Cancer science, 110(9), 2783-2793.

Kashefi, S., Ahmadi, H., Omranipour, R., Mahmoodzadeh, H., Jafarnezhad-Ansariha, F., Zavareh, F. T., & Mirshafiey, A. (2019). The anti-tumoral effect of β-D-mannuronic acid (M2000) as a novel NSAID on Treg cells frequency and MMP-2, MMP-9, CCL22 and TGFβ1 gene expression in pre-surgical breast cancer patients. Iranian Journal of Allergy, Asthma and Immunology, 80-90.

Li, X., Li, D., Shi, Q., Huang, X., & Ju, X. (2019). Umbilical cord blood‑derived Helios‑positive regulatory T cells promote angiogenesis in acute lymphoblastic leukemia in mice via CCL22 and the VEGFA‑VEGFR2 pathway. Molecular medicine reports, 19(5), 4195-4204.

Wu, S., He, H., Liu, H., Cao, Y., Li, R., Zhang, H., ... & Xu, J. (2018). CC motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer. Oncoimmunology, 7(6), e1433517.

Wei, Y., Wang, T., Song, H., Tian, L., Lyu, G., Zhao, L., & Xue, Y. (2017). CC motif chemokine 22 ligand (CCL22) concentrations in sera of gastric cancer patients are related to peritoneal metastasis and predict recurrence within one year after radical gastrectomy. Journal of Surgical Research, 211, 266-278.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Human Recombinant CCL22 protein, His Tag?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Alternative Versions

Mouse Recombinant CCL22 protein, His Tag (CAT#: V2LY-0526-LY8658)

Human CCL22 ELISA Kit (CAT#: V2LY-0626-LY4233)

Related Products

Rat Anti-CCL22 Recombinant Antibody (158113) (CAT#: CBMAB-C3224-LY)

Mouse Anti-CCL22 Recombinant Antibody (CBFYM-0927) (CAT#: CBMAB-M1076-FY)

Rat Anti-CCL22 Recombinant Antibody (CBFYM-0930) (CAT#: CBMAB-M1079-FY)

Mouse Anti-CCL22 Recombinant Antibody (CBFYM-0925) (CAT#: CBMAB-M1074-FY)

Mouse Anti-CCL22 Recombinant Antibody (CBXC-1253) (CAT#: CBMAB-C1520-CQ)

Human CCL22 ELISA Kit (CAT#: V2LY-0626-LY4233)

Rat Anti-CCL22 Recombinant Antibody (CBFYM-0929) (CAT#: CBMAB-M1078-FY)

Mouse Anti-CCL22 Recombinant Antibody (CBFYM-0926) (CAT#: CBMAB-M1075-FY)

Mouse Anti-CCL22 Recombinant Antibody (CBFYM-0928) (CAT#: CBMAB-M1077-FY)

Mouse Recombinant CCL22 protein, His Tag (CAT#: V2LY-0526-LY8658)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry